Trials / Withdrawn
WithdrawnNCT00710216
Comparison of Telbivudine Versus Lamivudine on the Early Dynamics and Kinetics of Viral Suppression in Chronic Hepatitis B
Randomized, Open-Label, Phase IV Trial in Nucleus(t)id-Naive Patients With Chronic Hepatitis B to Examine the Effect of Telbivudine Compared to Lamivudine on the Early Dynamics and Kinetics of Viral Suppression (Early-Viral-Dynamics Study)
- Status
- Withdrawn
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- University of Ulm · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This study examines the effect of telbivudine compared to lamivudine on the early viral kinetics in patients with chronic hepatitis B. The virus Kinetics is measured by the viral load (HBV-DNA) reduction in the serum during the first 12 weeks of therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lamivudine | 100 mg/day |
| DRUG | Telbivudine | 600 mg/day |
Timeline
- First posted
- 2008-07-04
- Last updated
- 2009-04-20
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT00710216. Inclusion in this directory is not an endorsement.